Ative to autografts and BMP therapies, suggesting an osteogenic potential for pre-clinical application. Our study gives helpful details in understanding the biocompatibility and bioactivity of calcium phosphate ceramics.Author ContributionsConceived and created the experiments: HRL MWA SHD SYK. Performed the experiments: HRL HJK JSK. Analyzed the information: HJK HRL SHD. Contributed reagents/materials/analysis tools: HRL MWA SHD SYK YSC. Wrote the paper: HRL SHD.PLOS 1 | www.plosone.orgPorous Bioceramics for an Osteogenic Response
Ann Hematol (2014) 93:1371380 DOI 10.1007/s00277-014-2063-ORIGINAL ARTICLEExpression of cereblon protein assessed by immunohistochemical staining in myeloma cells is related with superior response of thalidomide- and lenalidomide-based remedy, but not bortezomib-based treatment, in patients with numerous myelomaShang-Yi Huang Chung-Wu Lin Hsiu-Hsia Lin Ming Yao Jih-Luh Tang Shang-Ju Wu Yao-Chang Chen Hsiao-Yun Lu Hsin-An Hou Chien-Yuan Chen Wen-Chien Chou Woei Tsay Sheng-Je Chou Hwei-Fang TienReceived: 29 December 2013 / Accepted: 16 March 2014 / Published on the web: 1 April 2014 # The Author(s) 2014. This short article is published with open access at SpringerlinkAbstract Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Working with immunohistochemical (IHC) staining on paraffin-embedded bone marrow sections, the expression of CRBN protein in myeloma cells (MCs) was assessed in 40 relapsed/refractory MM (RRMM) patients who received lenalidomide/ dexamethasone (LD) and 45 and 22 newly diagnosed MM (NDMM) sufferers who received thalidomide/dexamethasone (TD) and melphalan/bortezomib/prednisolone (MVP), respectively. IHC staining had been scored on a scale representing the diffuseness and intensity of positive-staining MCs (variety, 08) as well as a score 4.Azoxymethane medchemexpress five was used for CRBN positivity (CRBN+) on a cut-point evaluation of all possible scores and response of TD and LD.N,N-Dicyclohexylcarbodiimide(DCC) Biological Activity When compared with CRBN+ NDMM patients, CRBN- NDMM patients had a lot more international staging technique (ISS) III (26 vs.PMID:24423657 61 , respectively; P=0.006). In the LD and TD cohorts, the response rate (RR) was larger in CRBN+ patientsS.Y. Huang (*) : H.H. Lin : M. Yao : J.L. Tang : S.J. Wu : Y.C. Chen : H.Y. Lu : H.A. Hou : C.Y. Chen : W.C. Chou : W. Tsay : S.J. Chou : H.F. Tien Department of Internal Medicine, National Taiwan University Hospital, B4:0509, No.7, Chung-Shan South Road, 10002 Taipei, R.O.C, Taiwan e-mail: [email protected] C.W. Lin Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan Y.C. Chen : W.C. Chou Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwanthan CRBN – individuals (LD 79 vs. 33 , respectively; P=0.005) (TD 75 vs. 29 , respectively; P=0.005); on the other hand, this trend was not observed within the MVP cohort. Inside the LD and TD cohorts, the constructive and negative prediction value of CRBN+ for treatment response was 79 and 67 and 75 and 71 , respectively. Multivariate analysis showed that CRBN+ was a substantial aspect linked with superior RR for LD and TD. The data recommend that expression of CRBN protein in MCs assessed using the IHC is a feasible method to predict the response of IMiDs in MM sufferers. Keyword phrases Cereblon . Immunohistochemistry . Immunomodulatory drugs . A number of myeloma . PrognosisIntroduction Many myel.
